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Context: Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical 
carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is 
considered an adrenolytic substance, but there is limited information on distinct effects on steroidogenesis. However, adrenal insufficiency 
and male hypogonadism are widely recognized side effects of mitotane treatment. 
Objective: Our objective was to define the impact of mitotane treatment on in vivo steroidogenesis in patients with ACC. 
Setting and Design: At seven European specialist referral centers for adrenal tumors, we analyzed 24-h urine samples (n_127) collected from 
patients with ACC before and during mitotane therapy in the adjuvant setting (n _ 23) or for metastatic ACC (n _ 104). Urinary steroid 
metabolite excretion was profiled by gas chromatography/mass spectrometry in comparison with healthy controls (n _ 88). 
Results: We found a sharp increase in the excretion of 6_-hydroxycortisol over cortisol (P_0.001), indicative of a strong induction of the 
major drug-metabolizing enzyme cytochrome P450 3A4. The contribution of 6_-hydroxycortisol to total glucocorticoid metabolites 
increased from2%(median, interquartile range 1–4%) to 56% (39–71%) during mitotane treatment. Furthermore, we documented 
strong inhibition of systemic 5_-reductase activity, indicated by a significant decrease in 5_-reduced steroids, including 5_-
tetrahydrocortisol, 5_-tetrahydrocorticosterone, and androsterone (all P _ 0.001). The degree of inhibition was similar to that in patients with 
inactivating 5_-reductase type 2 mutations (n _ 23) and patients receiving finasteride (n _ 5), but cluster analysis of steroid data revealed a 
pattern of inhibition distinct from these two groups. Longitudinal data showed rapid onset and long-lasting duration of the observed effects. 
Conclusions: Cytochrome P4503A4induction by mitotane results in rapid inactivation of more than 50% of administered hydrocortisone, 
explaining the need for doubling hydrocortisone replacement in mitotane-treated patients. Strong inhibition of 5_-reductase activity is in line 
with the clinical observation of relative inefficiency of testosterone replacement in mitotane-treated men, calling for replacement by 5_-
reduced androgens.  
  
Adrenocortical carcinoma (ACC) is a rare cancer, 
with an incidence of one to two cases per million 
per year and a poor prognosis, mostly due to a high risk 
of recurrence and limited therapeutic options (1). Mitotane 
[1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 
(o,p_-DDD)], an analog of the insecticide 
dichlorodiphenyltrichloroethane (DDT), has been used 
in the treatment of ACC since 1959 (2). Mitotane alone 
or in combination with cytotoxic chemotherapy is now 
established as the first-line treatment for metastatic 
ACC (3– 8) and is also widely used as adjuvant therapy 
in patients with apparently complete surgical removal 
of the primary tumor, especially if considered at high 
risk of recurrence (9). 
Despite the widespread use of mitotane in adrenal 
cancer, there is limited knowledge regarding the mechanisms 
underlying its antitumor activity, usually described 
as adrenolytic, i.e. a direct cytotoxic effect on 
the adrenal cortex (3, 10–12). There is also a paucity of 
information on distinct effects of mitotane on steroidogenesis, 
although it has been noted early on as an efficient 
treatment for Cushing’s syndrome (13–16), and 
in patients with normal adrenal function, mitotane therapy 
invariably results in adrenal insufficiency. There is 
in vivo evidence of enhanced production of cortisolbinding 
globulin and SHBG in mitotane-treated patients 
(17, 18). Notably, glucocorticoid replacement 
has to be administered in higher doses than usual in the 
general context of adrenal insufficiency to prevent adrenal 
crisis (3, 19). Mitotane-induced hypogonadism is 
frequently observed in male patients (18), but testosterone 
replacement often lacks clinical efficacy. 
We have recently shown that urine steroid metabolomics, 
i.e. the combination of steroid profiling by gas 
chromatography (GC)/mass spectrometry (MS) and 
computational data analysis, is a highly promising diagnostic 
tool for the detection of adrenocortical malignancy 
(20). Here we investigated the effects of mitotane 
on in vivo steroid production employing urinary steroid 
metabolomics for the analysis of 24-h urine samples 
from patients with adrenal cancer receiving mitotane 
for adjuvant treatment or metastatic disease. 
 
Subjects and Methods 
Subjects 
The 24-h urine samples from ACC patients were collected 
between 2006 and 2010 in seven specialist endocrine referral 
centers participating in the European Network for the Study of 
Adrenal Tumors (ENSAT; www.ensat.org), with approval of 
local ethical review boards and after obtaining written informed 
patient consent. We included 24-h urines from 100 patients (53 
women, 47 men; median age 52, range 16–80 yr) with histologically 
confirmed ACC who provided a total of 127 samples 
including 46 paired samples. Samples were collected before 
(ADJ, n _ 12) and during (ADJ_M, n _ 11) adjuvant mitotane 
therapy or before (MET, n_57) and during (MET_M, n_47) 
mitotane treatment for metastatic ACC. Samples during mitotane 
treatment were collected 3–4 months after initiation of therapy, 
i.e. at a time when therapeutic-range plasma mitotane levels 
(14–20 mg/liter) (21) generally had been achieved. None of the 
patients on adjuvant therapy had documented recurrence during 
this initial treatment period, and there were no major changes in 
tumor burden as documented by imaging in the metastatic group 
patients. Plasma mitotane levels were available for 50 of the 58 
patients on mitotane, all of them measured by HPLC (Lysosafe, 
Paris, France). Exclusion criteria included pregnancy and exposure 
to drugs known to induce expression and activity of hepatic 
cytochrome P450 (CYP) enzymes or to alter steroid secretion in 
any way, with the exception of glucocorticoid replacement therapy, 
which was routinely commenced in all mitotane-treated 
patients. 
For comparison, we employed 24-h urine samples of 88 
healthy controls (62 females, 26 males, age range 18–60 yr). In 
addition, for the assessment of 5_-reductase activity, we also 
compared the results with 24-h urine samples from patients with 
inactivating mutations in SRD5A2 encoding 5_-reductase type 
2 (n _ 23) and patients treated with the 5_-reductase type 2 
inhibitor finasteride (n _ 5). 
GC/MS urinary steroid metabolome analysis 
Measurement of 24-h urinary steroid metabolite excretion 
was carried out by GC/MS as previously described (20). In summary, 
free and conjugated steroids were extracted from urine by 
solid-phase extraction. Steroid conjugates were enzymatically 
hydrolyzed, reextracted, and chemically derivatized to form 
methyloxime trimethyl silyl ethers. GC/MS analysis of the urine 
samples was carried out on an Agilent (Santa Clara, CA) 5973 
instrument operating in selected-ion-monitoring (SIM) mode. 
This achieved sensitive and specific detection and quantification 
of 32 selected steroid metabolites chosen to include important 
representatives of steroid groups such as androgen metabolites, 
glucocorticoid metabolites, mineralocorticoid metabolites, and 
3_-hydroxy-_ (5) steroid metabolites (for details of the steroid 
metabolite profile see Ref. 20). 
After analysis of the entire profile, we calculated substrate 
metabolite to product metabolite ratios to assess the effects of 
mitotane on the in vivo net activity of distinct steroidogenic enzymes. 
This included 5_-reductase indicated by the ratio of 5_- 
tetrahydrocortisol to tetrahydrocortisol (5_-THF/THF), ratio of 
androsterone to etiocholanolone (An/Et), and ratio of 5_-tetrahydrocorticosterone/ 
tetrahydrocorticosterone (5_-THB/THB). 
As a measure of the activity of the major drug-metabolizing enzyme 
CYP3A4, we calculated the ratio of 6_-hydroxycortisol to 
cortisol (6_OHF/F) (22). Total steroid output was calculated as 
the sum of all quantified steroid metabolites with the exception 
of glucocorticoid metabolites because these also reflected exogenously 
administered glucocorticoid replacement. Total when 
used in this paper relates to the targeted compounds measured, 
which are dominant metabolites of hormonal steroids and their 
precursors. It does not include a multitude of minor metabolites. 
Statistical analysis 
Diagnostic ratios were presented as median and interquartile 
ranges [quartile 1 (Q1)–Q3]. In a first analysis, we considered all 
samples to be independent and employed nonparametric 
Kruskal-Wallis test and Dunn’s post hoc test to detect significant 
differences of individual ratios among the treatment groups. To 
take the paired nature of a subset of samples into account, we 
provided a separate analysis of the data employing Wilcoxon 
signed rank test. These analyses were carried employing Sigma- 
Plot (Systat Software Inc., Chicago, IL). 
Furthermore, we analyzed the influence of mitotane on 5_- 
reductase activity by performing multivariate analyses of the 
ratios reflecting 5_-reductase activity, An/Et, 5_-THF/THF, and 
5_-THB/THB. We performed principal component analysis 
(PCA) and linear discriminant analysis (LDA) (23) to generate 
two-dimensional representations of the data. Prior to analysis, 
the values of the ratios were log-transformed and normalized to 
zero mean and unit variance. The generated scatter plots allowed 
identification of clusters of similar ratio profiles. These analyses 
were done using the software MATLAB (Mathwork Inc., 
Natick, MA). 
Finally, we analyzed the association between plasma mitotane 
levels and the values of the steroid ratios indicative of 5_- 
reductase andCYP3A4activities by computing Spearman’s rank 
correlation coefficient, thereby accounting for the lack of normal 
distribution of the data. This analysis was carried out employing 
MATLAB. 
 
Results 
Mitotane down-regulates overall steroidogenesis 
First, we analyzed total steroid excretion to assess 
whether mitotane has an impact on the initial steps of 
steroidogenesis, namely CYP11A1 activity converting 
cholesterol to pregnenolone. For this analysis, we disregarded 
active glucocorticoid metabolites because the 
mitotane-treated patients invariably received hydrocortisone 
replacement therapy, which prevented a comprehensive 
assessment of endogenous glucocorticoid production. 
Comparing the remainder of total steroid 
excretion, we found that mitotane led to a significant 
down-regulation of overall steroidogenesis in metastatic 
ACC patients, as documented by a significant 
decrease in the sum of total androgen and mineralocorticoid 
metabolites (Fig. 1A and Table 1). This downregulation 
was significant for the larger group of metastatic 
ACC patients, decreasing both androgen and 
mineralocorticoid excretion to the level found in 
healthy controls, but failed to reach significance for the 
smaller adjuvant therapy group (Fig. 1A and Table 1). 
Of note, we found that the excretion of the 11-deoxycortisol 
metabolite tetrahydro-11-deoxycortisol did not 
differ when comparing steroid excretion before and after 
the initiation of mitotane therapy (Fig. 1B and Table 1), 
indicating that mitotane had no effect on 11_-hydroxylase 
activity, which converts 11-deoxycortisol to cortisol. 
Mitotane induces CYP3A4 activity and 
glucocorticoid inactivation 
After the initiation of mitotane treatment, 6_OHF/F 
showed a significant increase in both patients with metastatic 
disease and patients receiving adjuvant therapy (Fig. 
1, C and D, and Table 1 and Supplemental Table 1, published 
on The Endocrine Society’s Journals Onlinewebsite 
at http://jcem.endojournals.org), which was due to large 
increases in 6_-OHF excretion, indicative of a highly enhanced 
rate of inactivation of cortisol to 6_OHF, a conversion 
predominantly catalyzed by CYP3A4 (24–26). 
Before mitotane treatment, 6_OHF represented only 
1.3% (ADJ; Q1–Q3 1.0–2.6%) and 1.8% (MET; Q1–Q3 
0.8–4.2%), respectively, of total measured glucocorticoid 
metabolite excretion. By contrast, during mitotane treatment, 
63.8% (ADJ_M;Q1–Q348.9–70.2%) and 52.5% 
(MET_M; Q1–Q3 38.8–69.1%), respectively, of measured 
glucocorticoids were excreted as 6_OHF (Fig. 1E), 
suggesting rapid inactivation of exogenously administered 
hydrocortisone in the mitotane-treated patients. 
To exclude a significant contribution of the concurrent 
hydrocortisone replacement on the induction of CYP3A4 
observed in the mitotane-treated patients, we also studied 
the percentage of 6_OHF as part of total glucocorticoid 
excretion in patients with adrenal insufficiency, specifically 
30 patients on a regular-dose hydrocortisone replacement 
(10–30 mg/d) and 10 patients who received 
400 mg hydrocortisone during the 24-h period of urine 
collection. Results revealed that 6_OHF on regular hydrocortisone 
dose did not differ from healthy controls, 
whereas high-dose hydrocortisone slightly increased the 
median percentage of 6_OHF to just under 5% (Fig. 1E), 
confirming an only very minor contribution of hydrocortisone 
to the observed effect. 
GC/MS analysis of urine also showed a major increase 
in the excretion of normally minor metabolites formed 
throughCYP3A4activity but not selected for quantitation 
in this study, notably 6_- and 1_-hydroxylated metabolites 
of tetrahydrocortisone and the cortolones.Wedid not 
find an effect of mitotane on the steroid ratios reflective of 
11_-hydroxysteroid dehydrogenase type 1 or 2 activity. 
Mitotane inhibits 5_-reductase activity and 
androgen activation 
Introduction of mitotane therapy resulted in a highly 
significant decrease of several steroid metabolite ratios 
reflective of systemic 5_-reductase activity (Fig. 2 and Table 
1 and Supplemental Table 1). The degree of inhibition 
of 5_-reductase activity appeared to be similar to that 
observed in patients receiving treatment with the established 
5_-reductase type 2 inhibitor finasteride (n_5) and 
patients with inactivating 5_-reductase type 2 (SRD5A2) 
mutations (n_25) (Fig. 2 and Table 2). However, of note, 
the 5_-THB/THB ratio was more significantly inhibited 
by mitotane than observed in finasteride-treated or 
SRD5A2 mutant patients (Fig. 2 and Table 2). 
To examine the pattern of inhibition of 5_-reductase in 
further detail, we carried out cluster analysis employing 
both LDA and PCA; for this analysis, we considered all 
three ratios reflective of 5_-reductase activity and selected 
the patients receiving mitotane in the adjuvant setting to 
exclude any influence of tumor-related steroid production. 
Visualization of the data convincingly demonstrated 
strongly overlapping clustering of finasteride-treated patients 
and SRD5A2 mutant patients, who both have selective 
loss of 5_-reductase type 2 activity (Fig. 3A), indicative 
of similar ratio profiles in these two groups. By contrast, 
patients receiving mitotane are clearly separate in a second 
cluster (Fig. 3A). These findings were confirmed by an independent 
cluster analysis employing LDA (Fig. 3B). 
Longitudinal studies 
We analyzed the longitudinal course of the steroid ratios 
indicative of CYP3A4 activity (Fig. 4A) and 5_-reductase 
activity (Fig. 4, B and C) in five patients receiving 
adjuvant mitotane therapy for adrenocortical cancer. Results 
demonstrate a rapid onset of the effects of mitotane 
on the enzymatic activities of CYP3A4 and 5_-reductase, 
with the full extent of the effect already documented 
shortly after initiation of mitotane treatment (Fig. 4, A–C). 
We had the opportunity to document the diagnostic 
steroid ratios in one patient throughout 2 yr of adjuvant 
mitotane treatment followed by 2 yr of posttreatment observation 
(Fig. 4D). Plasma mitotane levels oscillated 
within the suggested therapeutic range (14–20 mg/liter) 
throughout the treatment period and only became undetectable 
1 yr after the last administration of mitotane. 
Concurrently, the steroid ratios indicative ofCYP3A4and 
5_-reductase activity started to recover but had not returned 
to pretreatment levels even 2 yr after the end of 
treatment (Fig. 4D), suggestive of long-lasting effects. 
Plasma mitotane levels and observed effects on 
steroidogenesis 
We analyzed the correlation between circulating 
plasma mitotane levels and the severity of CYP3A4 induction 
and 5_-reductase inhibition, respectively (Supplemental 
Fig. 1). This revealed a significant correlation between 
plasma mitotane levels and the induction of 
CYP3A4 [r _ 0.328, 95% confidence interval (CI) _ 
0.055–0.556, P _ 0.02] but not with the steroid ratios 
indicative of 5_-reductase activity (r__0.053,95%CI_ 
_0.327–0.229, P _ 0.71 for 5_THF/THF; r _ 0.106, 
95% CI__0.178–0.373, P _ 0.46 for An/Et) (Supplemental 
Fig. 1). Significant effects on the enzymatic activities 
were already observed at very low plasma mitotane 
levels and clearly below the suggested therapeutic range of 
14–20 mg/liter (21) (Supplemental Fig. 1). These findings 
are in line with the above-described observation that urine 
metabolite excretion showed the full effects as early as 1–2 
months after initiation of mitotane treatment (Fig. 4, 
A–C), when in most instances, plasma mitotane levels 
would not have reached the therapeutic range. 
 
Discussion 
This study documented comprehensive in vivo evidence 
for a strong inhibition of 5_-reductase activities and a 
significant induction of hepatic CYP3A4/5 activities in 
mitotane-treated patients, with an obvious and important 
impact on the requirements for glucocorticoid and 
androgen replacement during mitotane therapy. 
Evidence for alterations of cortisol metabolism and a 
link to hepatic enzyme activity was documented shortly 
after the introduction of mitotane for the treatment of 
adrenal cancer in 1959 (2). In 1964, two groups reported 
on altered cortisol metabolism resulting in increased 
urinary excretion of 6_OHF in guinea pig (27) 
and humans (28), respectively. Following up on these 
reports, two groups documented increased metabolism 
of pentobarbital (29) and hexobarbital and cortisol (30) 
by mitotane, postulating the induction of microsomal 
drug-metabolizing liver enzymes as the underlying 
cause. Work in the late 1980s demonstrated that the 
major drug-metabolizing enzyme CYP3A4 and to a 
lesser degree also CYP3A5 were the enzymes responsible 
for 6_-hydroxylation in liver and kidney (24 –26). 
Subsequently, the urinary 6_OHF/F has been widely 
implemented as a relative measure of CYP3A4/5 in vivo 
activity and several studies demonstrated a 4- to 7-fold 
increase in 6_OHF excretion in patients treated with 
rifampicin (25) or anticonvulsants (31). This study analyzing 
24-h urine samples from 127 patients collected 
before and during mitotane treatment demonstrated a 
10- to 15-fold increase in 6_OHF/F excretion, establishing 
mitotane as one of the strongest inducers of 
CYP3A4 activity. This convincingly corroborates a recent 
report on accelerated midazolam metabolism in 
four mitotane-treated patients suggestive of induction 
of CYP3A4 (and CYP3A5) activity (32). 
Early reports on hepatic enzyme induction by mitotane 
and also the invariable finding of highly increased cortisolbinding 
globulin levels during mitotane treatment (17) 
suggested an increased dose requirement for glucocorticoid 
replacement in mitotane-induced adrenal insufficiency. 
However, this has been widely recognized only in 
recent years, after a number of reports on adrenal crisis 
during mitotane treatment covered only with standard 
glucocorticoid replacement doses (19, 33). Consequently, 
the perceived rate of reported gastrointestinal toxicity during 
mitotane treatment has declined over recent years, because 
many of these signs and symptoms may have been 
reflective of incipient adrenal crisis. However, currently, 
there is no uniformly agreed dose regimen for glucocorticoid 
replacement during mitotane therapy and reported 
doses have varied widely (17, 18), with lower doses often 
reported as associated with a high incidence of vomiting 
and severe fatigue (18, 34). Our findings provide for the 
first time a reliable quantification of 6_-hydroxylation by 
mitotane, documenting the rapid excretion of 55–65% of 
glucocorticoids in the form of 6_OHF. 
Of note, CYP3A4/5 are responsible for not only the conversion 
of cortisol to 6_OHF but also for the 6_-hydroxylation 
of testosterone. Hypogonadism in mitotane-treated 
men initially manifests with a decreased free androgen index 
due to significantly increased SHBG levels that cannot be 
compensated for by up-regulated testosterone production as 
documented by increased total testosterone and LH levels 
(35). With time, gonadal testosterone production exhausts 
itself and circulating testosterone levels drop, accompanied 
by clinical manifestations of low testosterone 
including erectile dysfunction. However, testosterone replacement 
is often clinically ineffective and is complicated 
by an increased rate of gynecomastia (18). 
This study has yielded comprehensive evidence for a strong 
inhibition of 5_-reductase activities by mitotane. Importantly, 
the strong inhibition of 5_-reductase has significant consequences 
for androgen bioactivity, because the conversion of 
testosterone to the most potent androgen, 5_-dihydrotestosterone, 
will be greatly reduced. Consequently, thismayresult 
in enhanced conversion of testosterone to 17_-estradiol by 
widespread CYP19A1 (P450 aromatase) activity, which 
could explain the high incidence of gynecomastia in mitotane- 
treated patients. The lack of conversion of testosterone 
to 5_-dihydrotestosterone also represents a logical explanation 
for the frequent clinical observation of relative inefficiency 
of testosterone replacement with regard to erectile 
dysfunction. Our computational analysis of the ratios of 5_- 
to 5_-reduced steroids revealed a distinct pattern of global 
5_-reductase inhibition by mitotane compared with patients 
treated with a selective 5_-reductase type 2 inhibitor or patients 
with inactivating5_-reductase type2mutations.These 
results could indicate preferential inhibition of 5_-reductase 
type 1 by mitotane. 5_-Reductase inhibition could also have 
beneficial consequences in the context of androgen-producing 
ACC, where it would be likely to help ameliorate the 
clinical manifestations of androgen excess. 
A number of early studies addressed the impact of mitotane 
on adrenal steroidogenesis, reporting inhibitory effects 
of mitotane on 11_-hydroxylase, 3_-hydroxysteroid 
dehydrogenase, and 18-hydroxylase activities (36–39). 
However, in vivo studies by labeled isotope infusion were 
very limited in numbers, whereas in vitro studies were 
somewhat limited in their methodological approach. In 
our study, we found no evidence for distinct enzyme inhibition 
other than the above described strong inhibition 
of 5_-reductase activities and the induction of CYP3A4/5. 
Specifically, there was no change in 11-deoxycortisol metabolite 
excretion, rendering a significant change in 11_- 
hydroxylase (CYP11B1) enzymatic activity highly unlikely. 
However, we observed a down-regulation of 
overall steroidogenesis as quantified by the sum of total 
androgen and mineralocorticoid excretion; glucocorticoid 
metabolites were excluded for that analysis as altered due to 
the mandatory exogenous hydrocortisone replacement in 
mitotane-treated patients. These findings could indicate an 
inhibition of CYP11A1, i.e. P450 side-chain cleavage enzyme, 
as previously described in vitro (40), which would 
result in decreased conversion of cholesterol to pregnenolone 
and thus a decreased substrate entry flow into the steroidogenic 
pathways. This could contribute to the hypercholesterolemia 
that is a widely documented side effect of mitotane 
treatment and that has been previously suggested to be due 
to increased cholesterol synthesis as a consequence of mitotane- 
induced up-regulation of 3-hydroxy-3-methyl-glutarylcoenzyme 
A-reductase activity (41, 42). 
Our study provides a quantifiable measure for the 
strong induction of CYP3A4/5 activities by mitotane, 
which has the clinically most relevant consequences, including 
potential drug interactions in mitotane-treated patients, 
nicely summarized in a recent review (43). This has 
an impact not only on drugs needed for the treatment of 
mitotane-related side effects but, importantly, also on antitumor 
drugs including tyrosine kinase and mammalian 
target of rapamycin inhibitors and also chemotherapeutic 
agents included in the current 
first-line treatment for metastatic adrenal 
cancer (44). 
Our findings of strong and long-lasting 
inhibition of 5_-reductase and induction 
ofCYP3A4/5refine our understanding 
of the requirements for steroid 
replacement therapy in mitotane-treated 
patients. Our observation of a very rapid 
induction of CYP3A4 by mitotane suggests 
that lower glucocorticoid replacement 
doses, such as 25 mg cortisone 
acetate (18) equivalent to 15 mg hydrocortisone 
(45), may soon become 
inadequate and contribute to the gastrointestinal 
toxicity observed during 
the first months of mitotane treatment. 
Thus, we suggest that glucocorticoid 
replacement in mitotanetreated 
patients should be initiated 
and maintained with at least double 
the dose normally used in primary adrenal 
insufficiency, i.e. 40–50 mg hydrocortisone 
(equal to 75 mg cortisone 
acetate) rather than 20–25 mg hydrocortisone 
(equal to 37.5 mg cortisone 
acetate) per day. Dexamethasone 
should be avoided because it exerts a 
strong CYP3A4/5-inducing effect (46) 
that is likely to result in even more rapid 
inactivation. Whether urinary 6_OHF 
excretion can be used as a guide for dose 
adjustment will have to be examined by 
prospective studies. At present, the appropriateness 
of glucocorticoid replacement 
during mitotane therapy 
largely relies on clinical assessment and 
plasma ACTH measurements after the 
morning hydrocortisone dose, with increased 
levels suggestive of glucocorticoid 
underreplacement. Importantly, 
we should consider the use of 5_-reduced 
androgens, including synthetic 
androgens, for androgen replacement 
in mitotane-induced male hypogonadism, 
which may prove more effective 
and less prone to unwanted side effects than testosterone 
replacement therapy. Pregnancy needs to be added to the 
list of contraindications for mitotane therapy, and patients 
should have safe contraception in place because the strong 
inhibition of 5_-reductase activity would have a major 
impact on sexual differentiation, with a high likelihood of 
disordered sex development in the male fetus. 
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